← Leaderboards
Hancai Dan
Univ Of North Carolina Chapel Hill
$2,833,028
Attributed
$3,021,183
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $376.3K · FY2011–22$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,021,183 · 4
By mechanism
R01$1,771,417 · 1
R00$709,314 · 1
R56$376,310 · 1
K99$164,142 · 1
Top collaborators
- Kevin J Cullen1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Tikvah K Hayes$1,072,527
- Henry Shelton Earp$37,241,767
- Victoria Lin Bae-Jump$4,533,215
- David Harold Drewry$3,204,189
- Caleb D. Vogt$73,184
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsMutationBaseGrowthPhosphotransferasesInsightSignal PathwayLinkNew Therapeutic TargetOncogenicEfficacy TestingTissuesRegulationPten GeneInhibitor/AntagonistLeadCell SurvivalCellsComplexPlayClinical TrialsAnimalsCancer CellPathogenesis
Grant awards (11)
Targeting PI3Kalpha beta and the ErbB family of protein-tyrosine kinases in cisplatin-resistant head and neck squamous cell carcinomas (HNSCC)$376,310
R56 · FY2022 · DE · contact PI
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signaling$353,772
R01 · FY2021 · CA · contact PI
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signaling$353,772
R01 · FY2020 · CA · contact PI
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signaling$343,158
R01 · FY2019 · CA · contact PI
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signaling$353,772
R01 · FY2018 · CA · contact PI
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signaling$366,943
R01 · FY2017 · CA · contact PI
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression$238,663
R00 · FY2015 · CA · contact PI
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression$236,591
R00 · FY2014 · CA · contact PI
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression$234,060
R00 · FY2013 · CA · contact PI
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression$82,071
K99 · FY2012 · CA · contact PI
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression$82,071
K99 · FY2011 · CA · contact PI